CA2411386A1 - Therapie de combinaison pour le traitement des psychoses - Google Patents

Therapie de combinaison pour le traitement des psychoses Download PDF

Info

Publication number
CA2411386A1
CA2411386A1 CA002411386A CA2411386A CA2411386A1 CA 2411386 A1 CA2411386 A1 CA 2411386A1 CA 002411386 A CA002411386 A CA 002411386A CA 2411386 A CA2411386 A CA 2411386A CA 2411386 A1 CA2411386 A1 CA 2411386A1
Authority
CA
Canada
Prior art keywords
thiadiazol
tetrahydro
methylpyridine
component
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002411386A
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Harlan Edgar Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2411386A1 publication Critical patent/CA2411386A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une thérapie de combinaison comprenant un premier composant qui est un antipsychotique typique ou atypique et un second composant qui est un agoniste muscarinique. Cette thérapie est destinée au traitement des psychoses et d'autres troubles.
CA002411386A 2000-06-30 2001-06-18 Therapie de combinaison pour le traitement des psychoses Abandoned CA2411386A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21551600P 2000-06-30 2000-06-30
US60/215,516 2000-06-30
PCT/US2001/014863 WO2002003684A2 (fr) 2000-06-30 2001-06-18 Therapie de combinaison pour le traitement des psychoses

Publications (1)

Publication Number Publication Date
CA2411386A1 true CA2411386A1 (fr) 2002-01-10

Family

ID=22803282

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002411386A Abandoned CA2411386A1 (fr) 2000-06-30 2001-06-18 Therapie de combinaison pour le traitement des psychoses

Country Status (5)

Country Link
EP (1) EP1316203A2 (fr)
JP (1) JP2004502655A (fr)
AU (1) AU2001268055A1 (fr)
CA (1) CA2411386A1 (fr)
WO (1) WO2002003684A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428180D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Combination therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy
US7678363B2 (en) * 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2011011060A1 (fr) * 2009-07-22 2011-01-27 Puretech Ventures Procédés et compositions de traitement de troubles, ceux-ci étant améliorés par l'activation du récepteur muscarinique
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
AU2015250610B2 (en) 2014-04-23 2019-02-07 Takeda Pharmaceutical Company Limited Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease
CN107922403A (zh) 2015-06-26 2018-04-17 武田药品工业株式会社 作为胆碱能毒蕈碱m1受体的调节剂的2,3‑二氢‑4h‑1,3‑苯并噁嗪‑4‑酮衍生物
EP3366679B1 (fr) 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique
CA3180743A1 (fr) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprenant de la xanomeline et du trospium pour le traitement de troubles ameliores par l'activation du recepteur muscarinique
EP4091607A1 (fr) * 2021-05-18 2022-11-23 Karuna Therapeutics, Inc. Procédés de traitement de troubles du système nerveux central par l'activateur du récepteur muscarinique xanoméline et des antipsychotiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
AU2001268055A1 (en) 2002-01-14
EP1316203A2 (fr) 2003-06-04
JP2004502655A (ja) 2004-01-29
WO2002003684A3 (fr) 2003-03-13
WO2002003684A2 (fr) 2002-01-10

Similar Documents

Publication Publication Date Title
US5739151A (en) Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US20040023951A1 (en) Combination therapy for treatment of psychoses
IL126203A (en) A synergistic painkiller that contains olenzapine and another painkiller
CA2332814C (fr) Therapie combinee de traitement de la depression resistante
EP1863485A2 (fr) Ligand du recepteur nicotinique neuronal alpha7 et compositions antipsychotiques
NZ513966A (en) Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
EP1838310A1 (fr) Combinaison de la sabcoméline avec un agent neuroleptique dans le traitement de troubles psychotiques
EP0709094B1 (fr) Tétrahydropyridine oxadiazole ou thiadiazole pour traiter l'anxiété
CA2411386A1 (fr) Therapie de combinaison pour le traitement des psychoses
CA2167004C (fr) Agent pour le traitement de troubles mentaux associes a des troubles cerebrovasculaires
US20090258084A1 (en) Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia
US20090318414A1 (en) Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome
US6147093A (en) Methods for treating gastroesophageal reflux disease
CA2218019A1 (fr) Procede de traitement du sevrage nicotinique
EP1007050B1 (fr) L'olanzapine dans le traitement de la pharmacodependance
EP0709093A2 (fr) Utilisation d'une oxadiazole ou thiadiazole azabicyclique dans le traitement de l'anxiété
US5750541A (en) Method of treating schizophrenia
Ninan et al. Antagonism by pimozide of olanzapine‐induced hypothermia
US5545638A (en) Method of treating gastrointestinal motility disorders
MXPA00011353A (es) Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead